Skip to main content

Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
new molecular entities (NMEs)
Description

This request evaluated the uptake and length of follow-up time of New Molecular Entities (NMEs) approved in 2018 in the Sentinel Distributed Database (SDD).

  • Report 1 contains data on the first 29 of the 58 NMEs approved in 2018.
  • Report 2 contains data on the remaining 29 of the 58 NMEs approved in 2018.

The study period includes data from January 1, 2018 to March 31, 2021. We distributed this request to six Sentinel Data Partners on September 30, 2021.

 

Deliverables (2)
Sentinel Modular Program Report: Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis, Report 1 Sentinel Modular Program Report: Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2018 - March 31, 2021
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2016
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2011
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Sentinel Drug Analysis: Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Sentinel Drug Study: New Molecular Entities (NMEs) & Utilization Characterization